Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BIBF 1120 in recurrent glioblastoma multiforme
2010-021407-24Phase 2Completed
- Sponsor
- Rigshospitalet
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nintedanib in glioblastoma (GBM) (2 arms), sponsored by Rigshospitalet. Primary endpoint: Objective response rate. Started Oct 2010; status: completed.
02
Drugs
nintedanib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2010-021407-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021407-24.